Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen to Use Proteomics Technology to Develop Cancer Diagnostics with Johns Hopkins

NEW YORK, Nov 29 – ProteinChip-maker Ciphergen Biosystems said Wednesday that it would collaborate with Johns Hopkins University School of Medicine to develop proteomic diagnostic tests for cancer.

Ciphergen will use its ProteinChip System to discover and validate protein biomarkers in cancer serum samples provided by Johns Hopkins. The university will also provide the clinical expertise of its physicians and scientists.

Protein biomarkers may help doctors detect cancers earlier and distinguish forms of the disease. The markers may also prove to be protein drug candidates or point researchers toward potential drug targets.

Currently most diagnostic tests rely on a single marker. “The goal here is to come up with multi-marker diagnostic tests for disease that will have far more discriminating power,” said Matthew Hogan, CFO at Ciphergen. “Potentially you could diagnose a disease in an earlier state, but certainly you could do it more reliably.”

Hogan would not predict when the diagnostic tests would hit the market.

Ciphergen will provide financial support and technical assistance and would retain commercial rights to discoveries made through the collaboration.

Further financial terms of the deal were not disclosed .
The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.